Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies
- 4 March 2002
- journal article
- review article
- Published by Elsevier in Surgical Oncology
- Vol. 11 (1-2) , 13-23
- https://doi.org/10.1016/s0960-7404(02)00006-3
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- SUICIDE GENE THERAPY TOXICITY AFTER MULTIPLE AND REPEAT INJECTIONS IN PATIENTS WITH LOCALIZED PROSTATE CANCERJournal of Urology, 2000
- p53 MUTATIONS IN PROSTATE CANCER BONE METASTASES SUGGEST THAT SELECTED p53 MUTANTS IN THE PRIMARY SITE DEFINE FOCI WITH METASTATIC POTENTIALJournal of Urology, 1999
- Effects of Ca++ mobilization on expression of androgen-regulated genes: Interference with androgen receptor-mediated transactivation by AP-1 proteinsThe Prostate, 1997
- Clinical Trials in Relapsed Prostate Cancer: Defining the TargetJNCI Journal of the National Cancer Institute, 1996
- Herbimycin A Induces the 20 S Proteasome- and Ubiquitin-dependent Degradation of Receptor Tyrosine KinasesJournal of Biological Chemistry, 1995
- Approaches to Augmenting the Immunogenicity of Melanoma Gangliosides: From Whole Melanoma Cells to Ganglioside‐KLH Conjugate VaccinesImmunological Reviews, 1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- THE UBIQUITIN SYSTEM FOR PROTEIN DEGRADATIONAnnual Review of Biochemistry, 1992
- Leuprolide Therapy for Prostate Cancer An Association with Scintigraphic “Flare” on Bone ScanClinical Nuclear Medicine, 1990
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971